1. Home
  2. AORT vs IBRX Comparison

AORT vs IBRX Comparison

Compare AORT & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AORT
  • IBRX
  • Stock Information
  • Founded
  • AORT 1984
  • IBRX 2014
  • Country
  • AORT United States
  • IBRX United States
  • Employees
  • AORT N/A
  • IBRX N/A
  • Industry
  • AORT Medical/Dental Instruments
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AORT Health Care
  • IBRX Health Care
  • Exchange
  • AORT Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • AORT 2.0B
  • IBRX 2.3B
  • IPO Year
  • AORT 1993
  • IBRX N/A
  • Fundamental
  • Price
  • AORT $43.61
  • IBRX $2.34
  • Analyst Decision
  • AORT Strong Buy
  • IBRX Strong Buy
  • Analyst Count
  • AORT 6
  • IBRX 5
  • Target Price
  • AORT $40.63
  • IBRX $10.20
  • AVG Volume (30 Days)
  • AORT 620.4K
  • IBRX 8.9M
  • Earning Date
  • AORT 08-07-2025
  • IBRX 08-05-2025
  • Dividend Yield
  • AORT N/A
  • IBRX N/A
  • EPS Growth
  • AORT N/A
  • IBRX N/A
  • EPS
  • AORT N/A
  • IBRX N/A
  • Revenue
  • AORT $405,037,000.00
  • IBRX $56,600,000.00
  • Revenue This Year
  • AORT $14.99
  • IBRX $629.94
  • Revenue Next Year
  • AORT $10.80
  • IBRX $109.91
  • P/E Ratio
  • AORT N/A
  • IBRX N/A
  • Revenue Growth
  • AORT 7.44
  • IBRX 4227.22
  • 52 Week Low
  • AORT $21.97
  • IBRX $1.83
  • 52 Week High
  • AORT $45.07
  • IBRX $7.48
  • Technical
  • Relative Strength Index (RSI)
  • AORT 72.80
  • IBRX 43.72
  • Support Level
  • AORT $43.21
  • IBRX $2.28
  • Resistance Level
  • AORT $44.30
  • IBRX $2.43
  • Average True Range (ATR)
  • AORT 1.17
  • IBRX 0.15
  • MACD
  • AORT -0.13
  • IBRX 0.00
  • Stochastic Oscillator
  • AORT 64.41
  • IBRX 22.08

About AORT Artivion Inc.

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: